CNDAC
CNDAC is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC induces DNA damage and apoptosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 135598-68-4
- Formule: C10H12N4O4
- Masse moléculaire:252.23
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BC-3 | IC50 |
0.23 μM
Compound: 1, CNDAC
|
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
|
[PMID: 17402726] |
| DG-75 | IC50 |
0.21 μM
Compound: 1, CNDAC
|
Cytotoxicity against DG75 cells after 120 hrs by MTT assay
Cytotoxicity against DG75 cells after 120 hrs by MTT assay
|
[PMID: 17402726] |
| HOS-TE85 | IC50 |
6.8 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Osteosarcoma MNNG-HOS cell line
Inhibitory effect tested in vitro for the growth of Osteosarcoma MNNG-HOS cell line
|
[PMID: 1895307] |
| KHOS-321H | IC50 |
4.5 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Osteosarcoma KHOS-321H cell line
Inhibitory effect tested in vitro for the growth of Osteosarcoma KHOS-321H cell line
|
[PMID: 1895307] |
| MKN-1 | IC50 |
2.1 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN-1 cell line
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN-1 cell line
|
[PMID: 1895307] |
| MKN-28 | IC50 |
1.7 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN- 28 cell line
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN- 28 cell line
|
[PMID: 1895307] |
| MKN-7 | IC50 |
1.4 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN-7 cell line
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN-7 cell line
|
[PMID: 1895307] |
| MKN-74 | IC50 |
0.04 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN -24 cell line
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN -24 cell line
|
[PMID: 1895307] |
| NUGC-4 | IC50 |
5.2 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma NUGC-4 cell line
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma NUGC-4 cell line
|
[PMID: 1895307] |
| OST | IC50 |
6.4 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Osteosarcoma OST cell line
Inhibitory effect tested in vitro for the growth of Osteosarcoma OST cell line
|
[PMID: 1895307] |
| PC-13 | IC50 |
>100 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-13 cell line
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-13 cell line
|
[PMID: 1895307] |
| PC-3 | IC50 |
5.6 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-3 cell line
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-3 cell line
|
[PMID: 1895307] |
| PC-8 | IC50 |
4.6 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-8 cell line
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-8 cell line
|
[PMID: 1895307] |
| PC-9 | IC50 |
4.4 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-9 cell line
Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-9 cell line
|
[PMID: 1895307] |
| QG-56 | IC50 |
40 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Lung squamous-cell carcinoma QG-56 cell line
Inhibitory effect tested in vitro for the growth of Lung squamous-cell carcinoma QG-56 cell line
|
[PMID: 1895307] |
| SK-ES1 | IC50 |
2.2 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Osteosarcoma SK-ES-1 cell line
Inhibitory effect tested in vitro for the growth of Osteosarcoma SK-ES-1 cell line
|
[PMID: 1895307] |
| ST-KM-1 | IC50 |
2.8 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma ST-KM cell line
Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma ST-KM cell line
|
[PMID: 1895307] |
| SW480 | IC50 |
0.27 μg/mL
Compound: CNDAC
|
Inhibitory effect tested in vitro for the growth of colon adenocarcinoma SW-480 cell line
Inhibitory effect tested in vitro for the growth of colon adenocarcinoma SW-480 cell line
|
[PMID: 1895307] |
In Vitro
CNDAC has a unique mechanism of action: after incorporation into DNA, it induces single-strand breaks (SSBs) that are converted into double-strand breaks (DSBs) when cells go through a second S phase[1].
Lack of Rad51D and XRCC3 sensitizes cells to CNDAC (0-1 μM; 24 h)[1].
CNDAC (0-100 μM; 3 days) inhibits proliferation of HL-60 and THP-1 cells[2].
CNDAC (0-10 μM; 3-6 days) induces apoptosis in HL-60 and THP-1 cells[2].
CNDAC (6 μM; 48 h) induces cell cycle arrest in the G2 phase following a delayed S phase in HCT116 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF CHO cells
-
Concentration:0-1 μM
-
Incubation Time:24 h
-
Result:Inhibited cell survival with IC50s of 0.006, 0.32, 0.48 and 0.0053 μM against Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF cell lines, respectively.
-
Cell Line:HL-60 and THP-1 cells
-
Concentration:0-100 μM
-
Incubation Time:3 days
-
Result:Inhibited proliferation with IC50s of 1.5832 μM and 0.84 μM against HL-60 and THP-1 cells, respectively.
-
Cell Line:HL-60 and THP-1 cells
-
Concentration:0, 0.5, 1, 2, 3, 4, 5 and 10 μM
-
Incubation Time:3, 4, 5, and 6 days
-
Result:Induced apoptosis in both cells.
-
Cell Line:HCT116
-
Concentration:6 μM
-
Incubation Time:48 h
-
Result:36 and 36% of cells were arrested in late-S and G2/M phases, respectively.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CDF1 mice, P388 tumor model[4]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection, daily for 10 days
-
Result:Greatly increased the survival time and survival rate.
Chemical Information
-
CAS No. 135598-68-4
-
Masse moléculaire 252.23
-
Formule C10H12N4O4
-
SMILES
O=C(N=C(N)C=C1)N1[C@H]2[C@@H](C#N)[C@H](O)[C@@H](CO)O2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Pureté et documentation
Références
[1]. Liu XJ, et al. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. hin J Cancer. 2012 Aug;31(8):373-80. [Content Brief]
[2]. Jagan S, et al. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine. Adv Hematol. 2012;2012:727683. [Content Brief]
[3]. Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36. [Content Brief]
[4]. Azuma A, et al. Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem. 1993 Dec 24;36(26):4183-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)